Related by context. All words. (Click for frequent words.) 77 nonfatal MI 77 recurrent DVT 76 morphometric vertebral fractures 74 recurrent venous thromboembolism 74 reinfarction 73 thromboembolic complications 73 symptomatic intracranial 73 β blockers 73 recurrent VTE 72 rosuvastatin #mg 72 recurrent ischemia 72 cerebrovascular events 72 intima media thickness 72 colorectal adenoma 72 periprocedural 72 definite stent thrombosis 71 myocardial infarction stroke 71 PASI scores 71 ischemic cardiomyopathy 71 ipsilateral stroke 71 thrombotic complications 71 proximal DVT 71 ATACAND 71 FRAGMIN 70 glycated hemoglobin levels 70 NATRECOR ® 70 thromboembolism 70 salmeterol fluticasone 70 adenoma recurrence 70 eplerenone 70 hemorrhagic complications 70 thromboembolic events 70 serum calcium levels 69 perioperative mortality 69 ARIXTRA 69 thromboembolic 69 composite endpoint 69 severe exacerbations 69 XIENCE V PROMUS Stent 69 hematologic toxicity 69 postoperative complication 69 QTc prolongation 69 binary restenosis 69 desvenlafaxine succinate 69 XIENCE V demonstrated 69 carotid stenosis 69 lipid lowering agents 69 perioperative morbidity 69 unstable angina pectoris 69 patients undergoing CABG 69 HbA 1c levels 69 PSADT 69 arterial thromboembolic events 69 hsCRP levels 69 death reinfarction 69 STRIDE PD 69 Erythropoietic therapies may 69 idraparinux 69 haematologic 69 postoperative AF 69 hyperphenylalaninemia HPA due 69 cardiovascular hospitalizations 69 liver histology 69 nonfatal myocardial infarction 69 neutropaenia 68 postoperative mortality 68 Subgroup analysis 68 PRADAXA #mg 68 adenotonsillectomy 68 EXJADE 68 neonatal morbidity 68 cardiovascular hospitalization 68 artery stenosis 68 tirofiban 68 leucopenia 68 symptomatic DVT 68 doxorubicin docetaxel 68 rFVIIa 68 secondary efficacy endpoint 68 mg BID dose 68 fibrinolysis 68 elevated ALT 68 intravascular hemolysis 68 macrovascular events 68 CVD mortality 68 postintervention 68 intra abdominal abscess 68 platelet reactivity 68 hippocampal atrophy 68 Infusion Reactions Severe 68 dyslipidaemia 68 nonvertebral fractures 68 Postoperative complications 68 neutropenia dehydration dyspnea 68 coronary stenosis 68 nephrotoxicity 68 systemic embolism 68 nonvertebral fracture 68 androgen suppression 68 MACCE 68 antiplatelet drugs 68 beta blocker therapy 68 fluvastatin 68 upper gastrointestinal bleeding 67 histologic subtype 67 FluCAM arm 67 perioperatively 67 argatroban 67 prolonged QT interval 67 events MACE 67 carotid IMT 67 AST ALT 67 non valvular atrial 67 Kaplan Meier analysis 67 nondiabetic patients 67 nonfatal stroke 67 antithrombotic therapy 67 antioxidant supplementation 67 angiographic outcomes 67 postoperative pulmonary 67 myocardial reperfusion 67 nonfatal myocardial infarction MI 67 infarct size 67 multivariable analysis 67 serum phosphate 67 LV dysfunction 67 Febrile neutropenia 67 glycosylated hemoglobin HbA1c 67 intraventricular hemorrhage 67 postoperative atrial fibrillation 67 multivariate Cox 67 pericardial effusion 67 HF hospitalization 67 ventricular tachyarrhythmia 67 mycophenolate mofetil MMF 67 liver resection 67 everolimus eluting stents 67 ximelagatran 67 postprocedure 67 extrapyramidal symptoms 67 pyridostigmine 67 neurologic outcomes 67 thrombotic events 67 FDG PET imaging 67 BENICAR HCT 67 cardiovascular morbidity 67 baseline HbA1c 67 hepatorenal syndrome 67 lymphopenia 67 atherogenic dyslipidemia 67 Hypotension 67 foveal thickness 67 TAXUS Express Stent 67 liver transplant recipients 67 PLX STROKE targeting 67 Subgroup analyzes 67 post thrombotic syndrome 67 lumbar spine BMD 67 chemoradiation therapy 67 hyperalgesia 67 IIIa inhibitor 67 locoregional recurrence 67 NATRECOR R 67 adrenalectomy 66 plasma cortisol 66 rebleeding 66 androgen deprivation 66 paclitaxel eluting stents 66 Crohn Disease Activity 66 #.#/#.# mmHg [001] 66 PREZISTA r arm 66 prospective multicenter study 66 exploratory endpoints 66 recurrent glioblastoma multiforme 66 MADRS score 66 endometrial carcinoma 66 dose atorvastatin 66 oxycodone CR 66 keloid scarring 66 atrioventricular block 66 relapsed MM 66 neurologic complications 66 gastrointestinal perforation 66 warfarin sodium 66 hematologic parameters 66 aldosterone antagonist 66 postoperative morbidity 66 perioperative complications 66 serum estradiol 66 CYPHER Stent 66 intraoperative complications 66 vaso occlusive crisis 66 autonomic dysfunction 66 vertebral fracture 66 variceal bleeding 66 peripheral sensory neuropathy 66 venous thromboembolic disease 66 oral anticoagulation 66 NNT = 66 adjunctive placebo 66 coronary revascularization 66 VIIBRYD 66 SUVmax 66 triglyceride concentrations 66 SSc 66 urinary N telopeptide 66 pretest probability 66 TEAEs 66 Cardiopulmonary bypass 66 serum phosphorous 66 MS relapses 66 tipranavir r 66 echocardiographic parameters 66 timepoints 66 angiographic restenosis 66 pulmonary exacerbations 66 CIMZIA ™ 66 conditional logistic regression 66 intravesical therapy 66 lipid lowering therapy 66 refractory ischemia 66 neurologic progression 66 logistic regression analysis 66 atherothrombotic events 66 hypercalciuria 66 biochemical relapse 66 mixed hyperlipidemia 66 serum aminotransferase levels 66 coronary revascularization procedures 66 NPH insulin 66 paricalcitol 66 sustained ventricular tachycardia 66 symptomatic pulmonary embolism 66 hypoperfusion 66 neurocognitive deficits 66 noncardiac 66 revascularization procedures 66 torsade de pointes 66 severe neutropenia 66 TMP SMX 66 cerebral perfusion 66 chronic periodontitis 66 teriflunomide 66 nadroparin 66 angiographically 66 BYSTOLIC 66 CTEPH 66 liposomal amphotericin B 66 pyrexia mucositis sepsis febrile 66 hypercholesterolaemia 66 pulmonary artery banding 66 postoperative bleeding 66 pamidronate 66 tapentadol ER 66 myocardial infarctions 66 HSCT 66 myocardial infarction MI 66 hyperglycaemia 66 elevated IOP 66 periprocedural MI 66 PSA nadir 66 thromboprophylaxis 66 nonsevere 66 neutrophil counts 66 Endothelial dysfunction 66 eculizumab therapy 66 serum urate 66 neutropenia febrile neutropenia 66 antiplatelet medications 65 aspartate aminotransferase AST 65 serum creatinine levels 65 coagulation parameters 65 AGILECT R 65 postdischarge 65 CIMZIA TM certolizumab pegol 65 pain palliation 65 advanced adenoma 65 intraobserver 65 ACTEMRA TM 65 mycophenolate mofetil 65 bronchopulmonary dysplasia 65 dalteparin 65 Pulmonary embolism 65 postoperative chemotherapy 65 intravenous bisphosphonates 65 systemic corticosteroid 65 thrombocytopenic 65 nonoperative treatment 65 acromegalic patients 65 radiochemotherapy 65 glomerular filtration 65 Non inferiority 65 coadministration 65 febrile neutropenia 65 metabolic parameters 65 ARB telmisartan 65 embolic stroke 65 heparin induced thrombocytopenia 65 carotid atherosclerosis 65 postoperative infections 65 vasospasm 65 venous thromboembolic events 65 laboratory abnormalities 65 univariate 65 gastrointestinal toxicities 65 APTIVUS r 65 Index CDAI 65 aminotransferases 65 hematological parameters 65 alanine aminotransferase 65 VTE prophylaxis 65 carotid endarterectomy CEA 65 MGd 65 dose Iluvien 65 CR nPR 65 zonisamide SR 65 NSTE ACS 65 chemoradiotherapy 65 GH deficiency 65 revascularizations 65 peri procedural 65 HMG CoA reductase inhibitors 65 glycated hemoglobin HbA1c 65 solifenacin 65 graft dysfunction 65 elevated triglyceride levels 65 carotid artery stenting CAS 65 coronary intervention 65 corticosteroid dose 65 cytoreductive surgery 65 contrast induced nephropathy 65 aldosterone antagonists 65 riociguat 65 hsCRP 65 lumbar disk herniation 65 moderate renal impairment 65 IOP lowering 65 oral anticoagulant therapy 65 varices 65 rt PA 65 prespecified secondary 65 VT VF 65 fatal pulmonary embolism 65 hepatotoxicity 65 Thal Dex 65 percutaneous vertebroplasty 65 aspirin clopidogrel 65 Stent thrombosis 65 renal scarring 65 hypocalcemia 65 NYHA Class II 65 intracerebral haemorrhage 65 CP CPPS 65 lenalidomide dexamethasone 65 radiotherapy RT 65 urolithiasis 65 meta regression 65 unresectable HCC 65 pioglitazone HCl 65 Perforomist Inhalation Solution 65 alteplase 65 divalproex sodium 65 hypophosphatemia 65 PAOD 65 basal bolus regimen 65 5-FU/LV 65 octreotide LAR 65 grade cervical intraepithelial 65 concomitant medications 65 NIHSS 65 incidence ≥ 65 NIHSS score 65 Xelox 65 olmesartan 65 serum cortisol 65 graft occlusion 65 MMSE score 65 unfractionated heparin UFH 65 thrombolytic agents 65 pCR 65 gadobutrol 65 serum urate levels 65 microvascular complications 65 adenoidectomy 65 thrombolytic therapy 65 biochemical recurrence 65 abacavir lamivudine 65 receiving VICTRELIS 65 induce orthostatic hypotension 65 nasopharyngitis headache 65 subtrochanteric 65 carotid artery stenosis 65 tumor necrosis 65 endometrial hyperplasia 65 intravenous cyclophosphamide 65 QTc 65 hemodialysis patients 65 Renal dysfunction 65 Tasigna prolongs 65 β blocker 65 intact parathyroid hormone 65 vesicoureteral reflux 65 subclinical hypothyroidism 65 D dimer 65 otamixaban 65 efficacy endpoint 65 corrected QT interval 65 Primary endpoints 65 Thrombolysis 65 clinically meaningful reductions 65 steroid dexamethasone 65 somatostatin analog 65 Ejection Fraction 65 salivary flow 65 antiarrhythmic drug 65 NMIBC 65 postoperative complications 65 nadolol 65 pulmonary dysfunction 65 COPD exacerbation 65 nonfatal pulmonary embolism 65 fondaparinux 65 transaminase elevations 64 homocysteine concentrations 64 sternal wound infections 64 overt hepatic encephalopathy HE 64 clinically meaningful improvements 64 histological subtype 64 antiemetics 64 invasive candidiasis 64 hypomagnesemia 64 irbesartan 64 proliferative retinopathy 64 fasting insulin 64 clinicopathological features 64 ARCOXIA 64 intracranial hypertension 64 candidemia 64 symptomatic hyponatremia 64 neurologic sequelae 64 clodronate 64 CYPHER ® 64 antibiotic prophylaxis 64 hepatectomy 64 TORISEL 64 LAGB 64 hemodilution 64 serum triglycerides 64 thromboses 64 adrenal suppression 64 liver metastasis 64 cilostazol 64 intraventricular 64 multivariate analyzes 64 intracranial hemorrhage ICH 64 thoracoscopic lobectomy 64 cardiac dysfunction 64 malignant neoplasms 64 serum uric acid 64 asthma exacerbations 64 Multivariate logistic regression 64 HBeAg seroconversion 64 IV bisphosphonates 64 milrinone 64 ACE inhibitor ramipril 64 SCr 64 Symptom severity 64 EDARBI 64 treatment emergent AEs 64 chorioamnionitis 64 angiotensin converting enzyme inhibitor 64 hepatocellular carcinomas 64 cardiac troponin 64 carotid artery blockage 64 thyrotropin levels 64 QTc intervals 64 GOUT 64 HER2 expression 64 COPD exacerbations 64 airway hyperresponsiveness 64 renal dysfunction 64 GnRH agonists 64 corticosteroid therapy 64 apo B 64 acute myocardial infarction AMI 64 PRADAXA 64 glycosylated hemoglobin levels 64 opioid analgesia 64 variceal 64 intracranial bleeding 64 REMINYL ® 64 Intussusception 64 preserved ejection fraction 64 hepatic cirrhosis 64 macrovascular 64 Univariate analysis 64 P = .# 64 endometrial thickness 64 neurodevelopmental impairment 64 DULERA 64 decompensated heart failure 64 adjuvant tamoxifen 64 stenoses 64 NovoSeven ® 64 multivariate logistic regression 64 onset atrial fibrillation 64 SYNTAX trial 64 intravenous diuretics 64 ER CHOP 64 methacholine challenge 64 fluticasone salmeterol 64 conjunctival hyperemia 64 paroxysmal AF 64 arterial thromboembolism 64 MULTAQ 64 unfractionated heparin 64 Operative mortality 64 HMG CoA reductase inhibitor 64 ACTOS ® 64 ICD shocks 64 serum calcium 64 HIV HCV coinfected 64 calculated creatinine clearance 64 left ventricular systolic 64 clomipramine 64 TAXUS Stent 64 hypoxemia 64 recurrent myocardial infarction 64 femoral neck fracture 64 arterial thrombosis 64 LVEF 64 tertile 64 prognostic variables 64 ventricular remodeling 64 serum phosphate levels 64 myocardial ischemia 64 systemic hypotension 64 atherothrombotic disease 64 hepatic metastases 64 oncologic outcomes 64 fatal myocardial infarction 64 preoperative chemotherapy 64 NSTEMI 64 SGPT 64 perfusion defects 64 histologically confirmed 64 ischemia driven 64 REYATAZ r arm 64 comparator arm 64 symptomatic intracranial hemorrhage 64 cytopenias 64 #mg/day [001] 64 reoperations 64 Flu Cy 64 resuscitated cardiac arrest 64 fasting plasma 64 cerebral vasospasm 64 primidone 64 hyperacute 64 bolus dose 64 flutamide 64 NYHA functional class 64 evaluable subjects 64 prednisone prednisolone plus 64 autoantibody levels 64 multivariable adjusted 64 gross hematuria 64 gastrointestinal toxicity 64 Carotid endarterectomy 64 INCB# [003] 64 iodixanol 64 tumor regressions 64 virological response 64 univariate analyzes 64 NIH CPSI 64 Events MACE 64 posttreatment 64 Echocardiographic 64 QTcF 64 TNF antagonist 64 nonfasting triglyceride levels 64 adnexal mass 64 tolvaptan 64 postoperative hemorrhage 64 LHRH agonists 64 nonfasting triglycerides 64 macrovascular disease 64 electrophysiologic 64 antiandrogens 64 overt nephropathy 64 sirolimus eluting stents 64 bronchial hyperresponsiveness 64 resynchronization therapy 64 EDEMA3 trial 64 biologic DMARD 64 KRAS mutations occur 64 FOSRENOL ® 64 intravitreal injections 63 visceral metastases 63 coagulopathy 63 IPAH 63 ejection fractions 63 venous thromboembolisms 63 diameter stenosis 63 cinacalcet 63 anemia neutropenia 63 RAPAFLO R 63 inhospital 63 hip BMD 63 FOLPI 63 serum BDNF 63 nonischemic 63 reactogenicity 63 titrated glipizide 63 lopinavir r arm 63 systemic corticosteroids 63 hippocampal volume 63 ruptured aneurysms 63 ecchymosis 63 Skin sterol 63 fasting glucose levels 63 allogeneic stem cell 63 elevated creatinine 63 GnRH agonist 63 oral antidiabetic medication 63 oral rivaroxaban 63 antiarrhythmic drugs 63 ABCB1 63 coagulation abnormalities 63 certolizumab 63 fatigue asthenia 63 Carotid Revascularization Endarterectomy vs. 63 statin monotherapy 63 micafungin 63 unstable angina UA 63 activated partial thromboplastin 63 prospectively defined 63 adrenal insufficiency 63 salpingo oophorectomy 63 creatinine clearance 63 cerebral angiography 63 pneumonectomy 63 mL/min/#.# m 2 63 pulmonary toxicity 63 FDG uptake 63 bacteriuria 63 virologic failure 63 macroalbuminuria 63 TAXUS Liberte Long 63 Fasting plasma glucose 63 Folfox 63 noncardiovascular mortality 63 carotid plaque 63 plain radiographs 63 NEVO ™ 63 Adjuvant chemotherapy 63 metformin sulfonylurea 63 dose cytarabine 63 leiomyomas 63 Aggrastat ® tirofiban hydrochloride 63 afterload 63 Natalizumab 63 elevated serum creatinine 63 coronary artery occlusion 63 transcatheter closure 63 bowel resection 63 budesonide formoterol 63 deep venous thromboses 63 complement inhibitor eculizumab 63 renal flares 63 UA NSTEMI 63 myocardial infarction ventricular fibrillation 63 dose proportionality 63 neutropenia thrombocytopenia 63 osteoporotic vertebral compression fractures 63 ADCS CGIC 63 PEGINTRON TM 63 lanthanum carbonate 63 dysmenorrhoea 63 abnormal lipid 63 colesevelam HCl 63 Tumor shrinkage 63 HOMA IR 63 polyp recurrence 63 renal toxicity 63 HER2 overexpression 63 prostate TURP 63 enalapril 63 colectomy 63 underwent resection 63 CHD CVD 63 neutropenic fever 63 curative resection 63 cisplatin vinorelbine 63 platelet inhibitor 63 persistent pulmonary hypertension 63 HBeAg negative patients 63 colorectal liver metastases 63 invasive aspergillosis 63 F FDG PET 63 apolipoprotein B 63 conventional angiography 63 timepoint 63 DAPT 63 reflux esophagitis 63 Hydroxyurea 63 warfarin therapy 63 posttransplant 63 renal insufficiency 63 prostate cancer CaP 63 antiplatelet therapies 63 concurrent chemoradiation 63 spontaneous bacterial peritonitis 63 cTnI 63 bupropion SR 63 neurocognitive function 63 intracerebral hemorrhage ICH 63 atheroma volume 63 intracerebral hemorrhage 63 CMV infection 63 preterm newborns 63 ruboxistaurin 63 demonstrated clinically meaningful 63 anticoagulant warfarin 63 postop 63 myocardial fibrosis 63 p = NS 63 4mg/kg 63 extracranial 63 ALT flares 63 conventional DMARDs 63 syncope fainting 63 patients undergoing percutaneous 63 catheter angiography 63 canakinumab 63 atherothrombotic 63 artery occlusion 63 anemia hemoglobin 63 HbA1c levels 63 serum sodium 63 occlusive disease 63 salmeterol HFA MDI 63 dopaminergic therapy 63 hyperammonemia 63 cranial irradiation 63 headache nasopharyngitis 63 standard chemotherapy regimen 63 ExTRACT TIMI 63 intrathoracic 63 gastroduodenal 63 onset diabetes mellitus 63 repeat revascularization 63 HbA1C levels 63 gadolinium enhanced 63 conjugated equine estrogen 63 inhaled budesonide 63 ventricular dysfunction 63 serum homocysteine 63 pathologic fractures 63 myopathy rhabdomyolysis 63 primary patency 63 pelvic lymphadenectomy 63 primary aldosteronism 63 Hb A1C 63 complete cytogenetic response 63 N telopeptide 63 probiotic supplementation 63 antiplatelet medication 63 events TEAEs 63 Subarachnoid hemorrhage 63 venlafaxine XR 63 metastatic lung cancer 63 TAVR 63 lipid parameters 63 myocardial ischaemia 63 recurrent UTI 63 Carvedilol 63 myocardial viability 63 azacitidine 63 immunosuppressive regimen 63 methotrexate monotherapy 63 fosamprenavir 63 transfusion syndrome 63 paroxysmal atrial fibrillation 63 d dimer 63 delayed CINV 63 Secondary endpoints include 63 hyperkalemia 63 drug eluting stent implantation 63 saline placebo 63 mucosal inflammation 63 Toxicities 63 vasogenic edema 63 xanthine oxidase inhibitor 63 T2DM 63 ertapenem 63 serum leptin 63 ALT elevations 63 postoperative infection 63 Fontan procedure 63 % CI #.#-#.# [007] 63 Ishak fibrosis score 63 tamoxifen Nolvadex ® 63 dose statin therapy 63 hypercoagulable 63 variant angina 63 axillary node 63 GP IIb IIIa inhibitors 63 weekly subcutaneous injections 63 Myocardial infarction 63 cirrhotic patients 63 mg kg dose 63 VADT 63 eosinophilia 63 pyelonephritis 63 depressive symptom 63 DES implantation 63 pulmonary exacerbation 63 Venous thromboembolism 63 BEXXAR Therapeutic Regimen 63 atorvastatin #mg 63 OAB symptoms 63 p = #.# [003] 63 bivalirudin alone 63 aPTT 63 neutropenic sepsis 63 deep vein thromboses 63 symptom exacerbation 63 RSD# oral 63 Coronary Artery Bypass Graft 63 doxorubicin cyclophosphamide 63 surgical debulking 63 serum clusterin levels 63 dyssynchrony 63 arteriography 63 metastatic malignant 63 Multivariate analysis 63 spirometric 63 thromboembolic disease 63 DLTs 63 candesartan cilexetil 63 mucosal healing 63 dapagliflozin plus 63 allogeneic HSCT 63 secondary efficacy endpoints 63 nonhematologic adverse reactions 63 postoperative nausea 63 thrombocytopenia neutropenia 63 bypass grafting 63 tumor histology 63 NHANES III 63 Cypher Stent 63 proctitis 63 CHAMPION PCI 63 antiretroviral naïve 63 BPS IC 63 RE LY ® 63 surgical prophylaxis 63 dose colchicine 63 lymphocyte counts 63 RECORD1 63 detrusor overactivity 63 alanine aminotransferase ALT 63 platelet dysfunction 63 asthma exacerbation 63 airway responsiveness 63 #mg BID [001] 63 hematologic adverse 63 paroxetine Paxil 63 HDRS 63 serum IGF 63 pimecrolimus cream 63 hypoglycemic episodes 63 thrombophlebitis 63 systolic function 63 acute aortic dissection 63 esophageal varices 63 virologic breakthrough 63 interferon ribavirin 63 CIN3 63 intratympanic 62 pegylated liposomal doxorubicin 62 comorbid depression 62 multimodality therapy 62 bronchial reactivity 62 aspartate aminotransferase 62 hematological adverse 62 clopidogrel Plavix 62 receiving XGEVA 62 glucocorticoid therapy 62 ischemic lesions 62 aneurysmal subarachnoid hemorrhage 62 LNG IUS 62 Doxil ® 62 plasma triglycerides 62 hyperbilirubinemia 62 Psoriasis Area 62 macrolide antibiotic 62 covariate 62 pathologic fracture 62 AGILECT ® 62 WOMAC pain 62 Logistic regression 62 abdominal adiposity 62 glycoprotein IIb IIIa inhibitors 62 symptomatic paroxysmal AF 62 T1 weighted images 62 tiotropium 62 R# #mg BID 62 metachronous 62 hematological toxicity 62 OPCAB 62 cerebral infarction 62 platelet inhibition 62 metastatic bone 62 8mg/kg 62 generalized edema 62 direct thrombin inhibitors 62 cardiomegaly 62 Critical Limb Ischemia CLI 62 biochemical abnormalities 62 nodal metastases 62 analgesic medications 62 Tarceva TM 62 FOLFOX4 62 achieved statistical significance 62 left ventricular diastolic 62 GP IIb IIIa inhibitor 62 GAMMAGARD 62 SLNB 62 placebo dexamethasone 62 bivalirudin monotherapy 62 TYGACIL 62 bacterial prostatitis 62 neurodevelopmental outcomes 62 oral diclofenac 62 placebo controlled clinical 62 pegylated interferon alfa 2b 62 sacral neuromodulation 62 external genital lesions 62 Visual Analogue Scale VAS 62 lung resection 62 vasodilatation 62 RoACTEMRA 62 serum lipid levels 62 ALA PDT 62 leukopenia 62 nonmetastatic prostate cancer 62 sonographically guided 62 neuropsychiatric symptoms 62 atrioventricular valve 62 skeletal metastases 62 antibody titer 62 adjunctive ABILIFY 62 CABG coronary artery 62 acetabular dysplasia 62 vascular reactivity 62 hemoglobin A1c levels 62 GRNCM1 62 neovascular 62 transaminase levels 62 nicardipine 62 troponin T 62 INVEGA ® 62 antiangiogenic therapy 62 bypass graft CABG surgery 62 elotuzumab 62 tapentadol IR 62 hepatic enzymes 62 hydroxymethyl coenzyme 62 generalized seizures 62 severe renal impairment 62 intra articular injection 62 CYT# potent vascular disrupting 62 multivariable analyzes 62 vitreous floaters 62 MADIT CRT trial 62 EFFEXOR XR 62 coronary revascularizations 62 cardiac tamponade 62 serum PSA 62 serum PTH 62 tenecteplase 62 elective PCI 62 tHcy 62 neurocognitive outcomes 62 mitoxantrone plus 62 tamponade 62 glomerular filtration rate 62 elevated LDL cholesterol 62 caspofungin 62 CC genotype 62 deferoxamine 62 univariate analysis 62 symptomatic atrial fibrillation 62 DVT PE 62 hemodynamically significant 62 psoriatic arthritis PsA 62 hypoglycaemic episodes